CBA-1205, CBA-1535

Model: Antibody Drug Candidate

Booth No: N1107

Characteristic

”CBA-1205” ：Phase I
- A first-in-class antibody drug candidate targeting the DLK-1 tumor antigen.
- Clinical studies for hepatocellular carcinoma and melanoma are ongoing.
- The antibody has enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) through modification of the Fc glycan structure.
- The substance patent is registered in Japan, the US, EU, China and other countries.

"CBA-1535"：Phase I
- Trispecific antibody (Tribody) targeting 5T4 tumor antigen and CD3.
- Dose-escalating study is ongoing for solid tumors.
- Discovered utilizing multi-specific antibody platform technology (Tribody).
- CBA-1535 is a T-cell engager that induces the proliferation and activation of cytotoxic T cells in the presence of 5T4 antigen.
- The substance patent is registered in Japan, the US, EU, UK, China and other countries.

Other Products

Products you may be interested in

Highest Rated Products

Back

Menu

CBA-1205, CBA-1535

Characteristic

Other Products

Products you may be interested in

Highest Rated Products